Differential expression of fascin, E-cadherin and vimentin: Proteins associated with survival of cholangiocarcinoma patients

American Journal of the Medical Sciences

Volumn 346, Issue 4, 2013, Pages 261-268

  Mao, Xianhai ^a   Chen, Daojin ^a   Wu, Jinshu ^b   Li, Jian ^b   Zhou, Houping ^b   Wu, Yifei ^b   Duan, Xiaohui ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Hunan Provincial People's Hospital   (China)

Author keywords

Cholangiocarcinoma; E cadherin; Fascin; Immunohistochemistry; Vimentin

Indexed keywords

FASCIN; UVOMORULIN; VIMENTIN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER SURVIVAL; CELL DEDIFFERENTIATION; FEMALE; HEPATITIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROTEIN EXPRESSION; RISK FACTOR; TUMOR DIFFERENTIATION;

EID: 84885023472     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182707108     Document Type: Article

References (29)

1. Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet 2005;366:1303-14 (Pubitemid 41416587)
2. West J, Wood H, Logan RF, et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer 2006;94:1751-8 (Pubitemid 43924943)
3. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005;41:5-15 (Pubitemid 40066375)
4. Tang HH, Chang S, Wang XW, et al. Diagnostic and surgical therapeutic features of extrahepatic bile duct carcinoma without jaundice. World J Gastroenterol 2004;10:3060-1 (Pubitemid 39303064)
5. Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology 2004;66:167-79 (Pubitemid 38813042)
6. Huang JL, Biehl TR, Lee FT, et al. Outcomes after resection of cholangiocellular carcinoma. Am J Surg 2004;187:612-17 (Pubitemid 38596881)
7. Liotta LA, Mandler R, Murano G, et al. Tumor cell autocrine motility factor. Proc Natl Acad Sci U S A 1986;83:3302-6 (Pubitemid 16043024)
8. Ono S, Yamakita Y, Yamashiro S, et al. Identification of an actin binding region and a protein kinase C phosphorylation site on human fascin. J Biol Chem 1997;272:2527-33 (Pubitemid 27058546)
9. Adams JC, Clelland JD, Collett GD, et al. Cell-matrix adhesions differentially regulate fascin phosphorylation. Mol Biol Cell 1999;10: 4177-90
10. Adams JC. Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol 2004;16:590-6 (Pubitemid 39201245)
11. Xing P, Li JG, Jin F, et al. Fascin, an actin-bundling protein, promotes breast cancer progression in vitro. Cell Biochem Funct 2011;29: 303-10
12. Hayashi Y, Osanai M, Lee GH. Fascin-1 expression correlates with repression of E-cadherin expression in hepatocellular carcinoma cells and augments their invasiveness in combination with matrix metalloproteinases. Cancer Sci 2011;102:1228-35
13. Chen SF, Lin CY, Chang YC, et al. Effects of small interfering RNAs targeting fascin on gene expression in oral cancer cells. J Oral Pathol Med 2009;38:722-30
14. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740-6 (Pubitemid 37487967)
15. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-77
16. Zhang F, Ren G, Lu Y, et al. Identification of TRAK1 (trafficking protein, kinesin-binding 1) as MGb2-Ag: a novel cancer biomarker. Cancer Lett 2009;274:250-8
17. Korita PV, Wakai T, Ajioka Y, et al. Aberrant expression of vimentin correlates with dedifferentiation and poor prognosis in patients with intrahepatic cholangiocarcinoma. Anticancer Res 2010;30:2279-85
18. Settakorn J, Kaewpila N, Burns GF, et al. FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma. J Clin Pathol 2005;58:1249-54 (Pubitemid 41752767)
19. Anilkumar N, Parsons M, Monk R, et al. Interaction of fascin and protein kinase Calpha: a novel intersection in cell adhesion and motility. EMBO J 2003;22:5390-402 (Pubitemid 37279949)
20. Gotte M, Mohr C, Koo CY, et al. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 2010;29:6569-80
21. Puppa G, Maisonneuve P, Sonzogni A, et al. Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer 2007;96:1118-26 (Pubitemid 46608324)
22. Takikita M, Hu N, Shou JZ, et al. Fascin and CK4 as biomarkers for esophageal squamous cell carcinoma. Anticancer Res 2011;31:945-52
23. Zheng HC, Zheng YS, Xia P, et al. The pathobiological behaviors and prognosis associated with Japanese gastric adenocarcinomas of pure WHO histological subtypes. Histol Histopathol 2010;25:445-52
24. Gao HW, Yu CP, Lee HS, et al. Fascin, cortactin and survivin expression of melanocytic neoplasms and association with clinicopathological parameters and anatomic locations in Chinese people. Eur J Dermatol 2010;20:293-301
25. Okada K, Shimura T, Asakawa K, et al. Fascin expression is correlated with tumor progression of extrahepatic bile duct cancer. Hepatogastroenterology 2007;54:17-21 (Pubitemid 46511638)
26. Chen L, Yang S, Jakoncic J, et al. Migrastatin analogues target fascin to block tumour metastasis. Nature 2010;464:1062-6
27. Won KY, Kim GY, Lim SJ, et al. Prognostic significance of fascin expression in extrahepatic bile duct carcinomas. Pathol Res Pract 2009; 205:742-8
28. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90
29. Yap AS, Crampton MS, Hardin J. Making and breaking contacts: the cellular biology of cadherin regulation. Curr Opin Cell Biol 2007; 19:508-14. (Pubitemid 350016859)